TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25401387

Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard nutrient supply
Number of subjects: 50
Study: 22727477

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.5mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (Healthy Controls)
Number of subjects: 49
Study: 21994429

Group type: EXPERIMENTAL
Intervention: U-500R insulin (50 units)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: U-500R insulin (100 units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: U-100R insulin (50 units)
Number of subjects: 24

Group type: COMPARATOR
Intervention: U-100R insulin (100 units)
Number of subjects: 24
Study: 18337600

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (target BIS range, 40 to 60)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: ETAG-guided anesthesia (target ETAG range, 0.7 to 1.3 MAC)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 2000

Group type: COMPARATOR
Intervention: ETAG-guided anesthesia
Number of subjects: 2000
Study: 16600226

Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 257

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 257
Study: 12873780

Group type: EXPERIMENTAL
Intervention: 25 microg of micronized 17beta‐estradiol
Number of subjects: 1612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1612
Study: 10873167

Group type: EXPERIMENTAL
Intervention: Enhanced inactivated poliovirus vaccine (IPV) administered intramuscularly within 24 hours of birth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine vaccinations only (control group)
Number of subjects: 50
Study: 9351723

Group type: EXPERIMENTAL
Intervention: Early enteral feeding with an immune‐enhancing formula (IEF) via jejunostomy tube, started on postoperative day 1, goal of 25 kcal/kg per day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (CNTL) receiving intravenous crystalloid solutions
Number of subjects: 195
Study: 8471660

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day orally for at least 1 year
Number of subjects: 26

Group type: COMPARATOR
Intervention: Chemotherapy alone (melphalan 15 mg/m2 i.v. and prednisolone 60 mg/m2 orally)
Number of subjects: 26
Study: 2431027

Group type: EXPERIMENTAL
Intervention: Compound 48/80
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal skin sites (control)
Number of subjects: 0
Study: 30158069

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg, enteric-coated, once daily)
Number of subjects: 12546

Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 12546
Study: 27805885

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 60
Study: 24888818

Group type: EXPERIMENTAL
Intervention: Initial therapy (arm A)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Initial therapy (arm B)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Continue initial therapy (arm C1)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Change to alternative chemotherapy (arm C2)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Arms C1 and C2 combined
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Arms A, B, and C (C1 and C2 combined)
Number of subjects: 595
Study: 22071326

Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (100 μg/m(3))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clean air exposure (control)
Number of subjects: 0
Study: 20630159

Group type: EXPERIMENTAL
Intervention: Special intervention (Therapeutic Lifestyle Change diet education tailored to baseline stage of change)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 501
Study: 18789115

Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX)
Number of subjects: 21
Study: 15759056

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10141

Group type: EXPERIMENTAL
Intervention: Hirudin or Unfractionated heparin
Number of subjects: 10141
Study: 12583246

Group type: EXPERIMENTAL
Intervention: Integrating Western and traditional Chinese medicine (IWTCM) including Chinese medicine and allopurinol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Allopurinol only (Control group)
Number of subjects: 136
Study: 10051723

Group type: EXPERIMENTAL
Intervention: Active regime (hot washing and encasing covers + acaricide)
Number of subjects: 56
Study: 7756102

Group type: EXPERIMENTAL
Intervention: 3 mg DU 29894
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10 mg DU 29894
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1 mg flesinoxan
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 400 mg sulpiride
Number of subjects: 19
Study: 2110678

Group type: EXPERIMENTAL
Intervention: Tropical fish diet (500 g/day, rich in arachidonic acid and docosahexaenoic acid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Southern fish diet (500 g/day, rich in docosahexaenoic acid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Kangaroo meat diet (500 g/day, rich in linoleic and arachidonic acids)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vegetarian diet (low in fat, no 20‐ and 22‐carbon PUFA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 18
Study: 393429

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy regimen considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sequential chemotherapy regimen without considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Number of subjects: 63
Study: 30370782

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulating Play Intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 28356767

Group type: EXPERIMENTAL
Intervention: Guaifenesin 1200 mg BID
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Guaifenesin 600 mg BID
Number of subjects: 77

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 77

Group type: COMPARATOR
Intervention: Matched placebo (for 600 mg)
Number of subjects: 77
Study: 25466702

Group type: EXPERIMENTAL
Intervention: Biperiden (2 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of biperiden and citalopram
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23062170

Group type: EXPERIMENTAL
Intervention: Adolescent depressive symptoms (self-report)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Externalizing behaviors (parent report)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Adolescent depressive and externalizing symptom trajectories
Number of subjects: 361
Study: 21426666

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine with sorafenib
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine with placebo
Number of subjects: 30
Study: 19468954

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid supplementation
Number of subjects: 0
Study: 17400842

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily for 2 weeks, then 100 mg daily for 4 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (identical to sertraline)
Number of subjects: 99
Study: 15041109

Group type: EXPERIMENTAL
Intervention: Flutamide (FLU) 250 mg t.i.d. p.o.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA) 100 mg t.i.d. p.o.
Number of subjects: 310
Study: 14728869

Group type: EXPERIMENTAL
Intervention: Bioadhesive nonoxynol-9 gel
Number of subjects: 240

Group type: COMPARATOR
Intervention: Nonoxynol-9 suppository
Number of subjects: 240
Study: 10195374

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: GHRP‐2 2.0 microg/kg i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Tyr‐Ala‐HEX 2.0 microg/kg i.v.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 7756203

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (3 g daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 2184795

Group type: EXPERIMENTAL
Intervention: Low-tryptophan diet (160 mg/d for 24 hours) followed by a 16-amino acid drink
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control testing (placebo)
Number of subjects: 21
Study: 399960

Group type: EXPERIMENTAL
Intervention: 5 ml of meglumine ioserinate (single dose)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 10 ml of meglumine ioserinate (double dose)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: meglumine ioserinate (double dose)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: meglumine ioserinate
Number of subjects: 88
Study: 31525860

Group type: EXPERIMENTAL
Intervention: SCG DBS (subcallosal cingulate deep brain stimulation)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SCG DBS
Number of subjects: 27
Study: 30449012

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU of hCG in 10 µL culture medium 4 minutes before ET
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group receiving 10 µL of culture medium alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU of hCG
Number of subjects: 200
Study: 28839337

Group type: EXPERIMENTAL
Intervention: AL 441 mg every 4 weeks (n = 35)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: AL 882 mg every 6 weeks (n = 34)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: AL 1064 mg every 8 weeks (n = 70)
Number of subjects: 139
Study: 26210693

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24035461

Group type: EXPERIMENTAL
Intervention: Sensory-based intervention
Number of subjects: 50
Study: 22648627

Group type: EXPERIMENTAL
Intervention: Grape extract supplement containing 8 mg resveratrol (Stilvid®)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Grape extract (GE) without resveratrol
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 75
Study: 19243707

Group type: EXPERIMENTAL
Intervention: Long-term statin treatment for > or =6 months before PCI (statin group, 44 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No long-term statin treatment (nonstatin group, 56 patients)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term statin treatment for > or =6 months before PCI (statin group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No long-term statin treatment (nonstatin group)
Number of subjects: 100
Study: 17304422

Group type: EXPERIMENTAL
Intervention: Amikacin 20 mg/kg/d in one dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Amikacin 10 mg/kg/d every 12 hours (Control)
Number of subjects: 120
Study: 15054662

Group type: EXPERIMENTAL
Intervention: Elderly males (EM)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Young men (YM)
Number of subjects: 35
Study: 11575409

Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg kg(‐1) h(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg(‐1) h(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg(‐1) h(‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9880204

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + Prazosin 1 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hydralazine 30 mg + Isosorbide dinitrate 30 mg
Number of subjects: 17
Study: 7972362

Group type: EXPERIMENTAL
Intervention: Endurance training program for lower extremities
Number of subjects: 5
Study: 30654854

Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 36
Study: 29081250

Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training (LT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-intensity locomotor training (LT)
Number of subjects: 0
Study: 25803018

Group type: EXPERIMENTAL
Intervention: Video Capsule Endoscopy (VCE)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Push Enteroscopy (PE)
Number of subjects: 79
Study: 25131239

Group type: EXPERIMENTAL
Intervention: Midvastus approach (MV)
Number of subjects: 1188
Study: 21622538

Group type: EXPERIMENTAL
Intervention: Oral artesunate-amodiaquine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 56
Study: 19369828

Group type: EXPERIMENTAL
Intervention: Physically active (n = 511)
Number of subjects: 937

Group type: COMPARATOR
Intervention: Sedentary (n = 212)
Number of subjects: 937
Study: 16422753

Group type: EXPERIMENTAL
Intervention: Root canal treatment (RCT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Follow-up only (FU)
Number of subjects: 76
Study: 15630340

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retinal, retinyl palmitate, N-acetyl cysteine, Isotretinoin
Number of subjects: 0
Study: 11529827

Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone sodium succinate on anesthetic induction (n = 6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 13
Study: 9382758

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa 5142/1210-Flagella Vaccine IMMUNO
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 8516538

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 40 mg/12 hours from day 6 to 20, then 40 mg/8 hours from day 21 to 100
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2897303

Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: propranolol 40 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 31903689

Group type: EXPERIMENTAL
Intervention: Clinician-directed face-to-face therapy (n = 26)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Telepractice therapy via 'SwallowIT' (n = 26)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Patient self-directed therapy (n = 27)
Number of subjects: 79

Group type: COMPARATOR
Intervention: SwallowIT and clinician-directed models
Number of subjects: 79
Study: 29535646

Group type: EXPERIMENTAL
Intervention: e-Motional Training(R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 60
Study: 26529471

Group type: EXPERIMENTAL
Intervention: Four counseling sessions over 7 weeks with a message of sit less and move more
Number of subjects: 35

Group type: COMPARATOR
Intervention: Calcium for bone health (attention‐matched control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 24570011

Group type: EXPERIMENTAL
Intervention: Ultravision™ (device on)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (device off)
Number of subjects: 30
Study: 22515895

Group type: EXPERIMENTAL
Intervention: AH Plus with matched‐taper single‐cone technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MetaSEAL with matched‐taper single‐cone technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AH Plus with lateral condensation technique
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MetaSEAL with lateral condensation technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Instrumented but not obturated roots
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unobturated roots
Number of subjects: 90

Group type: COMPARATOR
Intervention: No instrumentation or obturation
Number of subjects: 90
Study: 21215227

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (0.5 mg/kg loading dose within 1 minute followed with infusion of 0.05 mg×kg(‐1)×min(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (loading dose: 3 mg/kg for 10 minutes, followed with intravenous infusion of 1 mg/min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg for 5 minutes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 18194504

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15807879

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 6 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study: 12006145

Group type: EXPERIMENTAL
Intervention: Nebulized taurolidine (4 mL 2% solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (4 mL 0.9% solution)
Number of subjects: 20
Study: 12198780

Group type: EXPERIMENTAL
Intervention: Lag 1 condition with targets in the same location
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lag 1 condition with targets in different locations
Number of subjects: 0
Study: 7869074

Group type: EXPERIMENTAL
Intervention: Cancer screening intervention, specific details not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for conducting screening case-control studies, specific details not available
Number of subjects: 0
Study: 1827615

Group type: EXPERIMENTAL
Intervention: 10 mg of cetirizine once daily
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: 60 mg of terfenadine twice daily
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: morning cetirizine
Number of subjects: 487
Study: 6779335

Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30928825

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/d)
Number of subjects: 7500

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 7500
Study: 30532205

Group type: EXPERIMENTAL
Intervention: μ-rhythm-phase-dependent burst-rTMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 0
Study: 27055923

Group type: EXPERIMENTAL
Intervention: Classical pharyngeal cavity reconstruction (group one)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Plastic suture of the inferior nasopharynx and exposure of the tonsillar fossa (group two)
Number of subjects: 48
Study: 25168620

Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily (QD) in patients with severe renal impairment
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Edoxaban with co-administration of P-glycoprotein (P-gp) inhibitors
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Edoxaban with IV dosing and co-administration of quinidine (a P-gp inhibitor)
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Edoxaban exposure-response analysis
Number of subjects: 1134
Study: 22374932

Group type: EXPERIMENTAL
Intervention: Group art therapy plus standard care
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Activity groups plus standard care
Number of subjects: 417

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 417
Study: 19283995

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fathers in PT group
Number of subjects: 32
Study: 17476001

Group type: EXPERIMENTAL
Intervention: Lokomat training (3 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional physical therapy (3 weeks)
Number of subjects: 16
Study: 15166013

Group type: EXPERIMENTAL
Intervention: Conventional doses of HRT (C‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.625 mg daily for 2 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lower doses of HRT (L‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg daily for 2 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Conventional doses of HRT (C‐HRT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lower doses of HRT (L‐HRT)
Number of subjects: 57
Study: 11704449

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study: 9209179

Group type: EXPERIMENTAL
Intervention: Low-viscosity milk (30 mPa.s)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Moderate-viscosity milk (80 mPa.s)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High-viscosity milk (1.9.10(3) mPa.s)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All test milks
Number of subjects: 13
Study: 7709781

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of nicardipine (2 mg injected three times each day for an average of 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (91 similar patients with cisternal drainage not treated with nicardipine)
Number of subjects: 50
Study: 3591260

Group type: EXPERIMENTAL
Intervention: 10(‐2) mol l‐1 calcium ascorbate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 ascorbic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (opioid premedication without ascorbate)
Number of subjects: 20
Study: 29305946

Group type: EXPERIMENTAL
Intervention: Whole-grain diet (50 g per 1000 kcal)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Refined-grain diet (isocaloric-matched)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 14
Study: 27273130

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil/levamisole
Number of subjects: 0
Study: 24660673

Group type: EXPERIMENTAL
Intervention: DVD group without any further support
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: DVD group with technical telephone coaching
Number of subjects: 660

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 660